)
Visual
test
Iteos Therapeutics
Iteos Therapeutics (ITOS) investor relations material
Iteos Therapeutics has been delisted
Iteos Therapeutics Q2 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2025 earnings summary6 Aug, 2025
Executive summary
Announced wind-down of clinical and operational activities following termination of lead program and GSK collaboration; merger with Concentra Biosciences pending, with expected completion in Q3 2025.
Lead antibody candidate belrestotug program discontinued after failing to meet key clinical endpoints; all related trials and collaboration with GSK ended.
EOS-984 and EOS-215 programs remain as assets for potential disposition under the merger's contingent value rights (CVRs).
Substantial doubt exists about ability to continue as a going concern absent completion of the merger or alternative transaction.
Financial highlights
No revenue recognized in Q2 2025; $35.0M license and collaboration revenue recognized in Q2 2024 from GSK milestone.
Net loss of $78.7M for Q2 2025, compared to $7.1M in Q2 2024; net loss of $113.3M for six months ended June 30, 2025, up from $45.3M year-over-year.
Research and development expenses rose to $57.3M in Q2 2025 from $36.7M in Q2 2024, mainly due to GSK termination payment.
Restructuring costs of $16.3M recorded in Q2 2025 related to severance and wind-down.
Cash and cash equivalents of $207.8M and available-for-sale securities of $382.2M as of June 30, 2025.
Outlook and guidance
Merger with Concentra expected to close in Q3 2025, subject to conditions including minimum $475M net cash at closing.
If merger is not completed, company may pursue alternative strategic transaction or dissolution and liquidation.
No plans to resume R&D if merger fails; wind-down of operations expected to be substantially complete in Q3 2025.
What is the status of EOS-984 program?
Describe the terms of the WuXi Agreement.
Detail the CVRs in the Concentra merger.
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Latest summaries
- TimeTickerHeadlineOpen
- 5 FebGEVO
Scaling low-carbon fuel production and software, targeting major growth and plant expansion. - 5 FebARES
AUM climbed 29% to $622.5B, with record fundraising, earnings, and a 20% dividend increase. - 5 FebFR
FFO per share rose 11.7% in 2025, with strong leasing and a 12.4% dividend increase. - 5 FebBTU
Centurion Mine launch and strong cash flow position drive higher 2026 met coal volumes and returns. - 5 Feb033780
Record earnings, robust shareholder returns, and global expansion mark 2025; moderate growth targeted for 2026. - 5 FebWST
Integrated PFS system accelerates development, reduces risk, and simplifies compliance. - 5 FebCMS
2025 adjusted EPS up 8%+ to $3.61, 2026 guidance raised, $24B plan drives growth. - 5 FebCHILE
2025 net income reached CLP 1,192,262 million, with strong capital and digital-driven growth ahead. - 5 FebORLY
Record 2025 results with 6% sales and 10% EPS growth, plus strong 2026 outlook. - 5 FebOWL
AUM surpassed $300 billion in 2025 amid record fundraising and double-digit earnings growth.
Iteos Therapeutics
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Iteos Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of a new generation of immuno-oncology therapeutics for patients living with cancer. The company is engaged in pioneering the development of highly differentiated immunotherapies, including two clinical-stage programs targeting novel, validated immuno-oncology pathways. These efforts aim to advance the treatment landscape for cancer patients by focusing on innovative therapeutic approaches that harness the body's immune system to fight cancer more effectively. Iteos Therapeutics is headquartered in Watertown, MA, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage